Title

Why Do Trials for Alzheimer's Disease Drugs Keep Failing? a Discontinued Drug Perspective for 2010-2015

Department

neurology

Document Type

Article

Abstract

Introduction: There are dozens of drugs in development for AD with billions of dollars invested. Despite the massive investment in AD drugs and a burgeoning pipeline, there have been more setbacks and failures than treatment successes. Areas covered: The classes of drugs that have failed to date include the monoclonal antibodies, the gamma secretase inhibitors, dimebon, neurochemical enhancers, and one tau drug. Data for these compounds were sought through a PubMed search and a clinicaltrials.gov search. Expert opinion: The obvious question to be posed is: Why are they failing? Is the treatment of symptomatic dementia too late? Are the therapeutic targets incorrect? Are the clinical methodologies imprecise, misleading, or inaccurate? This review summarizes the drugs that have failed during 2010–2015 and offers possible theories as to why they have failed.

Medical Subject Headings

neurology

Publication Date

2017

Publication Title

Expert Opinion on Investigational Drugs

ISSN

13543784

Volume

26

Issue

6

First Page

735

Last Page

739

Digital Object Identifier (DOI)

10.1080/13543784.2017.1323868

This document is currently not available here.

Share

COinS